The stock is up 14.29 percent over the past four weeks. The counter outperformed the S&P 500 by 22.3 percent with out-performance increases to 11.12 percent. According to the Feb. 22 report, the company “did not lose steam” from an intraday rally and hit a high of +0.8794.
The increases are crucial for the company, which received a letter from Nasdaq on Feb. 20 noting the company’s stock hasn’t been above $1 for 30 consecutive days, which is a requirement for the Nasdaq Listing.
Amedica has until Aug. 18 to get bid price above $1 for 10 or more consecutive days. The company’s 52-week low is 0.5501. Last December, the company announced restructuring for a better focus on core competencies and Sonny Bal, MD, recently took over as CEO.
More articles on orthopedic devices:
LDR, Amendia, Precision Spine & more—18 key notes
MIS instruments market: 7 key trends
DJO’s net loss down to $90.5M in 2014—10 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
